Crinetics Pharmaceuticals Inc (CRNX) Expected to Post Quarterly Sales of $330,000.00

Equities research analysts expect Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) to announce sales of $330,000.00 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Crinetics Pharmaceuticals’ earnings. The lowest sales estimate is $200,000.00 and the highest is $550,000.00. Crinetics Pharmaceuticals reported sales of $660,000.00 in the same quarter last year, which would suggest a negative year over year growth rate of 50%. The company is expected to announce its next quarterly earnings report on Thursday, August 29th.

On average, analysts expect that Crinetics Pharmaceuticals will report full-year sales of $1.18 million for the current fiscal year, with estimates ranging from $400,000.00 to $2.20 million. For the next fiscal year, analysts expect that the business will report sales of $0.00. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.04. The company had revenue of $0.37 million during the quarter, compared to the consensus estimate of $0.25 million. Crinetics Pharmaceuticals had a negative net margin of 1,303.31% and a negative return on equity of 26.96%.



Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. HC Wainwright assumed coverage on shares of Crinetics Pharmaceuticals in a research report on Thursday, February 14th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Crinetics Pharmaceuticals in a research report on Monday, March 11th. They set an “overweight” rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Crinetics Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $37.20.

Shares of CRNX stock traded down $0.13 during trading hours on Tuesday, hitting $25.45. 5 shares of the company were exchanged, compared to its average volume of 50,516. The company has a market cap of $608.77 million and a price-to-earnings ratio of -11.41. Crinetics Pharmaceuticals has a fifty-two week low of $19.23 and a fifty-two week high of $42.00. The company has a quick ratio of 21.03, a current ratio of 18.04 and a debt-to-equity ratio of 0.04.

In related news, major shareholder Vivo Capital Fund Viii, L.P. sold 417,000 shares of Crinetics Pharmaceuticals stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $22.25, for a total value of $9,278,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ventures Iv L.P. 5Am sold 154,839 shares of Crinetics Pharmaceuticals stock in a transaction on Monday, March 18th. The shares were sold at an average price of $24.25, for a total transaction of $3,754,845.75. The disclosure for this sale can be found here.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its position in Crinetics Pharmaceuticals by 23.0% in the 1st quarter. FMR LLC now owns 3,614,288 shares of the company’s stock worth $82,262,000 after buying an additional 675,749 shares during the last quarter. Opaleye Management Inc. bought a new stake in Crinetics Pharmaceuticals in the 1st quarter worth approximately $1,661,000. Marshall Wace LLP bought a new stake in Crinetics Pharmaceuticals in the 1st quarter worth approximately $775,000. Charles Schwab Investment Management Inc. lifted its position in Crinetics Pharmaceuticals by 18.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 40,217 shares of the company’s stock worth $916,000 after buying an additional 6,343 shares during the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in Crinetics Pharmaceuticals in the 1st quarter worth approximately $43,000. 69.19% of the stock is owned by institutional investors and hedge funds.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Recommended Story: Special Dividends

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.